Table 3.

Patients with de novo HLA DSA at one yr post-transplant, de novo HLA DSA class, mean fluorescence intensity (MFI), and one-yr protocol biopsy characteristics

Age, gender KTx no. HLA mm (A-B-DR)	dn DSA class, specificity (MFI)	∑ MFI	Banff score	Banff classification	Immunosuppression at one yr
ABOi n = 1/20
Patient no. 1a 37 yr, male, 1.KTx (1-1-1)	Class I A2 (3500) B8 (2800) Class II DR17 (1170) DQ2 (5700)	13 170	i1t0v0 ptc0, g1 C4d3 pos. cv0, ah0, ci1, ct1	ABMR	Standard
ABOc 6/60
Patient no. 2 22 yr, male 1.KTx (1-0-1)	Class I A68 (1500)	1500	i2t1v0, ptc1, g1 C4d3 pos. cv0, ah0, ci1, ct1	ABMR + borderline	MMF reduced
Patient no. 3 29 yr, male 1.KTx (1-1-1)	Class II DQ7 (7700)	7700	i2t1v0, ptc2, g0 C4d0 neg. cv0, ah0, ci1, ct1	ABMR + borderline	MMF reduced
Patient no. 4 42 yr, male 1.KTx (0-1-1)	Class II DQ7 (4300)	4300	i0t1v0 ptc0, g0 C4d3 pos. cv0, ah1, ci1, ct1	Suspicious ABMR + borderline	Standard
Patient no. 5 55 yr, male 1.KTx (1-1-1)	Class II DQ7 (6000)	6000	i0t0v0 ptc0, g0 C4d0 neg. cv1, ah1 ci0, ct0	No rejection	Standard
Patient no. 6 66 yr, male 1.KTx (1-1-1)	Class II DQ6 (2200)	2200	i0t1v0 ptc1, g1 C4d0 neg. cv0, ah0, ci1, ct1	ABMR + borderline	Low tacrolimus trough level around 3
Patient no. 7 27 yr, male 1.KTx (1-1-1)	Class II DR52 (1700) DR17 (3100) DQ2 (9500)	14 300	i0t0v0 ptc0, g0 C4d3 pos. cv0, ah0, ci0, ct1	No rejection	Standard Comment Three months later-mixed ABMR i3t3v0, ptc3, g1, C4d3 pos.

KTx no., kidney transplantation number; HLA mm, human leukocyte antigen mismatch; dn DSA, de novo donor-specific antibody; ABOi, ABO incompatible; ABOc, ABO compatible; ABMR, antibody-mediated rejection; MMF, mycophenolate mofetil/enteric-coated mycophenolate sodium; i, interstitial inflammation; t, tubulitis; v, vasculitis; ptc, peritubular capillaritis; g, glomerulitis; C4d, complement component 4d; pos, positive; neg, negative; cv, intima fibrosis; ah, arteriolar hyalinosis; ci, interstitial fibrosis; ct, tubulus atrophy.

^aAnti-blood group antibodies IgM/IgG < 1.